September is Newborn Screening Awareness Month Newborn Screening is a modern medical practice many believe to be the most successful public health program in United States history. Since the 1960s, every infant born in America receives a heel prick within the first 48 hours of life. The resulting dried blood is then tested for a …
Newborn Screening Awareness Month: Creating a Federalized Screening Program Read More »
Featured in Pharmaceutical Outsourcing: Losing a single patient during a clinical trial can mean giving up crucial data and extending trial timelines, often resulting in significant financial repercussions for trial sponsors and their research partners.
Prioritizing Patient Safety, Recruitment, and Retention Almost two years after its initial outbreak, COVID-19 continues to cause numerous problems for sites, sponsors, and patients enrolled in clinical trials. New disease variants are creating an increase in cases, resulting in additional barriers to clinical trial participation. For patients in the rare disease space, these issues further …
COVID-19 Solutions: Prioritizing Safety, Recruitment, and Retention Read More »
Scott Gray, founder and CEO Clincierge, discusses the biggest changes in clinical trial operations, patient centricity, and shares a few stories about obstacles overcome during the coronavirus pandemic during a podcast session with Applied Clinical Trials.
In the August issue of InFocus, Clincierge shares actionable ways to overcome participation barriers for rare diseases. Steps to overcoming participation barriers include coordinating access on a global scale, removing geographic barriers to participation, and leveraging patient coordinators to ensure patient comfort.
Research teams who appreciate the unique needs of rare disease patients and invest in a white-glove approach on behalf of trial participants can reduce barriers to participation. For sponsors, clinical study teams, and site staff, this means easier patient recruitment at the beginning of a study and fewer dropouts throughout the duration of the trial—with …
Reducing Barriers to Participation in Clinical Trials for Rare Disease Read More »
The medical community and cultural opinion agree: clinical trials need diversity. It’s our job to serve affected populations, but we cannot do that if we don’t have an appropriate representation of these populations in our research. Minorities are often more at risk for the disease yet are egregiously underrepresented in clinical trials. Understanding why and …
Achieving Clinical Trial Diversity Through Actionable Steps Read More »
Diversity in Clinical Trials: Going Beyond Why to How Diversity is a hot-button issue within the global medical community. The industry continues to seek effective and sustainable solutions to create more diverse clinical trials. Our CEO, Scott Gray, joined Michael Causey, Editor-in-Chief, ACRP TV, to share his insight and practical methods for improving diversity in …
Diversity in Clinical Trials: Going Beyond Why to How Read More »
Developing a patient-centric and compliant study is a top priority for any team. Understanding the importance of Institutional Review Boards (IRB) and Ethics Committees (EC) and their role is critical to a successful clinical trial.
View the results of our recent research to explore how effective patient support strategies can reduce barriers, increase retention, and improve outcomes in rare disease clinical trials in our latest eBook.
